Mesoblast shares continue slide, but this ASX biotech stock is soaring 23%!

Mesoblast shares have yet to recover from Friday's 57% crash.

| More on:
Two happy scientists analysing test results in a lab

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Mesoblast Ltd (ASX: MSB) shares are sliding again on Tuesday.

Shares in the ASX biotech company are down 3.7% at time of writing to 40 cents a share.

That puts Mesoblast shares down a painful 55% since the opening bell rang on 3 January.

But it's not all bad news in the ASX biotech space today.

Recce Pharmaceuticals Ltd (ASX: RCE) is setting the bar high, soaring 23% today. Shares in the ASX biotech stock are currently swapping hands for 75 cents apiece.

Here's what's happening.

Mesoblast shares remain out of favour

First, the bad news.

Mesoblast shares have yet to find support after suffering through a devastating fall on Friday.

That came after the company exited a trading halt to announce that the United States Food and Drug Administration (FDA) had not approved its stem cell therapy, remestemcel-L, for use in the US.

Mesoblast has been trying to gain FDA approval for its treatment for a number of years. But the agency again held the process back, saying it needed more data to support marketing approval for remestemcel-L in the world's top economy.

Although the company said it would continue to pursue future approval, Mesoblast shares crashed 56.9% on Friday and tumbled another 12.8% yesterday.

What's sending the Recce Pharmaceuticals share price soaring?

Moving on from the continuing slide for Mesoblast shares to this rocketing ASX biotech stock, investor enthusiasm looks to be stoked by a positive announcement released this morning.

Recce is developing a new class of synthetic anti-infectives.

One of those is RECCE 327 Gel, an experimental compound not yet market-approved for use in humans.

According to the release, RECCE 327 showed a positive clinical response in the treatment of multiple antibiotic-resistant infections under the Therapeutic Goods Administration (TGA) Special Access Scheme Category A.

The compound was administered via a new Gel formulation, with the ex vivo burn wound study indicating a 99.99% reduction against Methicillin-resistant Staphylococcus aureus.

Commenting on the promising results, Recce Pharmaceuticals CEO James Graham said:

Antibiotic resistance is globally recognised as one of the greatest threats to human health today. To see Recce making a difference to patients in such great medical need before us, is another welcomed sign of new hope in the fight against drug-resistant superbugs.

The company said that clinical trial preparations are underway across multiple unmet medical needs.

How have Mesoblast shares been performing relative to Recce?

While both ASX biotech stocks remain down over the past 12 months, Recce has outperformed Mesoblast.

Since this time last year, Recce shares are down 18% while Mesoblast shares have sunk 54%.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a young scientist using a digital tablet while working in a lab.
Share Gainers

If you'd put $20,000 in this ASX healthcare stock during COVID-19, you'd have $257,000 now

You could have become filthy rich in just 4 years. Just think about that.

Read more »

Shot of a young scientist using a laptop while conducting research in a laboratory.
Healthcare Shares

Sonic Healthcare shares hit 52-week low as analysts take a scalpel to targets

Analysts have sharpened the knives after the latest blood-sucking half year at Sonic Healthcare.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
52-Week Highs

Medibank share price hits 52-week high on US tech partnership

This private health insurer's shares are scaling new heights today. But why?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

What is the dividend growth rate of CSL stock?

CSL's dividends are worth more than what meets the eye.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Earnings Results

Sonic share price sinks after first-half profit crash

The healthcare company's profits have almost halved.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

The market is placing 'zero value' on this ASX 200 stock's booming pipeline

Up 78% in a year, these experts reckon there’s more outperformance to come from this top ASX 200 stock.

Read more »

Shot of a senior scientist looking stressed out while working in a lab.
Healthcare Shares

This ASX 200 healthcare share is diving 13% as short sellers take aim

A short seller is describing this company's Daybue product as a 'flop'.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Healthcare Shares

Guess which ASX 300 healthcare stock is surging 13% on FDA news

Here's what's getting investors excited today.

Read more »